NPS isovaleramide migraine study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NPS' alifatic amide neuromodulator isovaleramide (NPS 1776) fails to show significance in a proof-of-concept study in moderate to severe migraine "due to a higher than expected placebo response," NPS says Oct. 11. A positive response was seen in 60% of patients receiving a high dose (800 mg), 64% receiving a low dose (400 mg), and 56% of placebo patients in the 189-patient Phase IIa trial. NPS "will complete its evaluation of data from this study, and plans to continue to explore the development of NPS 1776 in other indications." Other potential indications for isovaleramide include bipolar disorder and epilepsy...
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.